vs
Side-by-side financial comparison of FIRST COMMONWEALTH FINANCIAL CORP (FCF) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
FIRST COMMONWEALTH FINANCIAL CORP is the larger business by last-quarter revenue ($133.7M vs $86.8M, roughly 1.5× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 13.0%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 5.5%).
First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FCF vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $133.7M | $86.8M |
| Net Profit | $37.5M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 28.1% | — |
| Revenue YoY | 13.0% | 17.7% |
| Net Profit YoY | 14.8% | — |
| EPS (diluted) | $0.37 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $133.7M | — | ||
| Q4 25 | $137.9M | $86.8M | ||
| Q3 25 | $136.0M | $67.5M | ||
| Q2 25 | $131.0M | $60.0M | ||
| Q1 25 | $118.0M | $49.3M | ||
| Q4 24 | $120.4M | $73.7M | ||
| Q3 24 | $121.2M | $58.6M | ||
| Q2 24 | $120.2M | $31.1M |
| Q1 26 | $37.5M | — | ||
| Q4 25 | $44.9M | — | ||
| Q3 25 | $41.3M | $-91.3M | ||
| Q2 25 | $33.4M | $-111.7M | ||
| Q1 25 | $32.7M | $-116.2M | ||
| Q4 24 | $35.8M | — | ||
| Q3 24 | $32.1M | $-83.5M | ||
| Q2 24 | $37.1M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 40.9% | -84.7% | ||
| Q3 25 | 38.1% | -140.7% | ||
| Q2 25 | 32.1% | -189.8% | ||
| Q1 25 | 34.8% | -245.8% | ||
| Q4 24 | 37.1% | -117.5% | ||
| Q3 24 | 33.4% | -152.1% | ||
| Q2 24 | 38.7% | -327.6% |
| Q1 26 | 28.1% | — | ||
| Q4 25 | 32.5% | — | ||
| Q3 25 | 30.4% | -135.3% | ||
| Q2 25 | 25.5% | -186.2% | ||
| Q1 25 | 27.7% | -235.5% | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 26.5% | -142.7% | ||
| Q2 24 | 30.9% | -312.2% |
| Q1 26 | $0.37 | — | ||
| Q4 25 | $0.44 | — | ||
| Q3 25 | $0.39 | — | ||
| Q2 25 | $0.32 | $-0.33 | ||
| Q1 25 | $0.32 | $-0.36 | ||
| Q4 24 | $0.35 | $-0.24 | ||
| Q3 24 | $0.31 | $-0.28 | ||
| Q2 24 | $0.36 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $154.9M | — |
| Stockholders' EquityBook value | $1.6B | $698.6M |
| Total Assets | $12.3B | $913.2M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M |
| Q1 26 | $154.9M | — | ||
| Q4 25 | $261.7M | — | ||
| Q3 25 | $262.1M | — | ||
| Q2 25 | $262.4M | — | ||
| Q1 25 | $262.7M | — | ||
| Q4 24 | $263.0M | — | ||
| Q3 24 | $136.3M | — | ||
| Q2 24 | $136.6M | — |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $698.6M | ||
| Q3 25 | $1.5B | $702.3M | ||
| Q2 25 | $1.5B | $698.5M | ||
| Q1 25 | $1.4B | $767.9M | ||
| Q4 24 | $1.4B | $710.4M | ||
| Q3 24 | $1.4B | $773.5M | ||
| Q2 24 | $1.4B | $768.5M |
| Q1 26 | $12.3B | — | ||
| Q4 25 | $12.3B | $913.2M | ||
| Q3 25 | $12.3B | $904.9M | ||
| Q2 25 | $12.2B | $907.4M | ||
| Q1 25 | $11.8B | $966.7M | ||
| Q4 24 | $11.6B | $910.4M | ||
| Q3 24 | $12.0B | $991.1M | ||
| Q2 24 | $11.6B | $964.3M |
| Q1 26 | 0.10× | — | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.18× | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $187.5M | $-52.6M | ||
| Q3 25 | $49.5M | $-78.7M | ||
| Q2 25 | $30.4M | $-67.4M | ||
| Q1 25 | $55.9M | $-103.7M | ||
| Q4 24 | $129.5M | $-73.3M | ||
| Q3 24 | $53.6M | $-59.0M | ||
| Q2 24 | $22.7M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $171.5M | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | $113.9M | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 124.3% | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | 94.6% | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 11.7% | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | 12.9% | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.18× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 1.71× | — | ||
| Q4 24 | 3.61× | — | ||
| Q3 24 | 1.67× | — | ||
| Q2 24 | 0.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FCF
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
